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A B S T R A C T
Objective: Isoniazid (INH) and rifampin (RIF) are the most effective first line antibiotics 
against Mycobacterium tuberculosis. Mutations in several genes  determine resistance of 
M. tuberculosis to INH, with the most common gene target of katG, and resistance to RIF 
is due to mutation in rpoB gene. The aim of present study was to assess the mutations 
in the regions related to RIF and INH resistance. 
Methods: We characterized 80 clinical isolates of confirmed M. tuberculosis to analyze 
the most commonly observed INH and RIF mutations. PCR analysis and sequencing 
were used to detect mutations related to RIF and INH resistance. The multiplex allele-
specific-PCR (MAS-PCR) was performed as a comparative assay and for evaluation of 
this method.
Results: The sequencing of the 250-bp region of katG codon 315, revealed point 
mutations at 5 different codons in 13.7% of the M. tuberculosis isolates. The sequencing 
of the 270-bp central region of the rpoB gene revealed point mutations at 7 different 
codons in 12 (15%) of the M. tuberculosis isolates. The results obtained with MAS-PCR are 
in accordance with PCR-sequencing with high sensitivity and specificity for katG315, 
inhA15, and rpoB (531, 516, 526). 
Conclusion: The results of this study suggested that molecular techniques can be used as 
a rapid tool for the identification of drug resistance in clinical isolates of M. tuberculosis. 
Both DNA sequencing and MAS-PCR yielded high sensitivity for the detection of RIF and 
INH mutations and detecting multi-drug resistant tuberculosis cases.
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Introduction
Drug-resistant tuberculosis (TB) is particularly alarming 
and an important threat to the control of the disease 
globally.1 There is also much concern that the TB condition 
will aggravate with the growing human immunodeficiency 
virus (HIV) pandemic worldwide, as the host immune system 
can weaken and become susceptible to TB endogenous 
reactivation and exogenous re-infection.2 Effective TB 
control is challenged by HIV infection and drug-resistant 
TB, a fatal combination. In the most recent studies on the 
anti-tuberculosis drug resistance surveillance, a global 
project has been published by the World Health Organization 
(WHO) and the International Union Against Tuberculosis and 
Lung Disease (IUATLD).3 The ratio of multidrug resistance 
(MDR), denoting resistance to at least isoniazid (INH) and 
rifampin (RIF), in new cases ranged from 0 to 22.3%. The 
highest proportion of MDR-TB reported was 60% among 
previously treated cases. It has been estimated that 489,139 
cases of MDR-TB emerged in 2006, and the global proportion 
of such resistance among all cases amounted to 4.8%.3 
The strategy of directly observed treatment short course 
(DOTS) is achieving substantial progress in the control of 
tuberculosis worldwide. However, MDR-TB has emerged 
as a new challenge, especially in developing countries. 
This is mainly due to lack of funding to support the 
treatment of MDR-TB with second line anti-TB drugs.4 
The emergence of MDR strains of Mycobacterium tuberculosis 
(MTB) poses a significant threat to the global control of 
tuberculosis. Worldwide surveillance has demonstrated 
that drug-resistant strains are now widespread and reaching 
alarmingly high-levels in certain countries.5 MDR-TB is a 
potentially untreatable, transmissible disease associated 
with a high mortality.6 Expeditious identification of 
antimicrobial susceptibility patterns of MTB is essential for 
the control of MDR-TB.
INH is the most widely used first-line anti-tuberculosis 
drug. Mutations in several genes determine resistance 
of MTB to INH, but the most common mutations are in 
codon 315 of katG & rpoB gene mutations in M. tuberculosis. 
katG accounts for 50-95% of INH-resistant clinical isolates. 
Resistance to INH can also occur by mutations in the promoter 
region of inhA operon, causing over-expression of inhA, or 
by mutations at the inhA active site, lowering the inhA affinity 
to the INH-NAD adduct.7,8 Mutations in inhA or its promoter 
region are usually associated with low-level resistance and are 
less frequent than katG mutations.9,10 RIF is also an important 
first-line drug for the treatment of TB. The vast majority of RIF 
resistance is caused by mutations located in the 81-base pair 
(bp) region of the rpoB gene. Mutations at positions 531, 526 and 
516 are among the most frequent mutations in RIF-resistant 
strains.11 Most of the frequent point mutations associated with 
drug resistance involve the codons screened in the present 
study, as reported by previous investigations.9,12,13 In this 
investigation, we have studied the prevalence of predominant 
mutations related to INH and RIF in TB patients in Ahvaz, Iran.
Material and methods
M. tuberculosis isolates
A total of 80 clinical MTB isolates were collected from the TB 
reference laboratory of Khuzestan, Iran, over one year period 
from February 2010 to February 2011. The isolates were 
selected from positive cultures on Lowenstein (LJ) medium 
after 4-6 weeks growth at 37°C.
DNA extraction
For DNA extraction from MTB colonies harvested from the 
surface of LJ medium, the simple boiling method was used.14 
In brief, a few colonies were dissolved in TE (Tris-EDTA) 
buffer and boiled at 100°C for 15 minutes with subsequent 
precipitation in a 1200 x g refrigerated centrifuge at 4°C for 
3 min.  The supernatant containing DNA was used as template 
for PCR amplification.
PCR assay
For preliminary detection of MTB, the PCR assay was performed 
using the primers based on the IS6110 gene.15 The primers used 
for PCR amplification and detection of mutations in katG 315, 
inhA 15 and rpoB genes are listed in Table 1. The primers for 
detecting resistance in RIF  were designed to amplify a 270-bp 
fragment of the rpoB gene, containing the 81-bp hypervariable 
region comprising positions with the most frequent mutations 
in RIF-resistant strains (rpoB codons 511, 513, 516, 522, 526, 531, 
and 533).16,17
The amplification reactions were performed in a final 
volume of 20 µL, containing 0.2 µg of genomic DNA, 20 pmol of 
each primer and 10 µL of AmpliTaq Gold master mix (ABI, USA). 
PCR was performed in an Eppendorf thermal cycler (Germany), 
using the following condition for amplification of the IS6110 
gene: initial denaturation at 95°C for 5 min, one cycle of 95°C 
for 20 s, 45°C for 360 s and 72°C for 120 s, followed by 30 cycles 
of 95°C for 20 s, 62°C for 60 s and 72°C for 180 s.
Genes  primer  
sequence            
Amplicon size (bp) 
IS6110  5’-CTCGTCCAGCGC-CGCTTCGG-3’        130
  5’-CCTGCGAGCGTAGGCGTCGG-3’
rpoB  5-GGTCGGCATGTCGCGGATGG-3’         270
5-GTATGCGACGGGTGCA-CGTC-3
katG315 5-GGCCC-CGAACCCGAGGCTGC-3         250
 5-AACGGGTCCGGG-ATGGTGCCG-3
inhA15 5- CCGCCGATGAGAGCGGTGAGC-3       245
5- CCACTGCTTTGCCGCCACCGC-3 
Table 1 - Primers used for the amplification of  IS6110, 
rpoB, katG, inhA and sequencing15-17
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Fig. 1 - Agarose gel electrophoresis of PCR assays for  
the identification of (a) IS6110 gene. 1, DNA size marker ;  
2, negative control; 3-9 and 11-13, positive samples (130bp); 
14, positive control.
Fig. 2 - Agarose gel electrophoresis of PCR assays for the 
identification of (a) katG codon315- inhA- rpoB. 1, DNA size 
marker; 2-5, katG codon315 (250bp); 6 and 7, inhA (245bp); 
8, negative control;  9-11, rpoB (270bp).
Amplification conditions for katG 315 genes were 
initial denaturation at 95°C for 5 min followed by 30 cycles 
of denaturation at 95°C for 15 s, annealing at 66°C for 15 s, 
and extension at 72°C for 15 s, and a final extension at 72°C 
for 5 min. The PCR amplification for the rpoB was in a similar 
manner except that the annealing temperature was lowered 
to 62°C.
Gene sequencing
PCR products were collected and sent for sequencing analysis 
at Bioneer Company, Korea.
Multiplex allele-specific PCR (MAS-PCR)
MAS-PCR method was used for simultaneous detection of the 
katG gene codon 315 and rpoB gene codons 516, 526, and 531, 
and mabA-inhA15. In this assay, in each allele-specific primer, 
3′ end was located to pair with the base of the related codons 
where most point mutations have been found to compare with 
the wild-type sequences of strain H37Rv. Thus, the wild-type 
allele-specific fragment was amplified when no mutation 
existed at a related codon. No allele-specific PCR product was 
generated when there was a mutation at the targeted codons.
The amount of each pair of primers in MAS-PCR was 
balanced to achieve acceptable amplification of all target 
regions. For each MAS-PCR reaction, a standard 35 µL final 
reaction was used. Each final volume  included 8 primers of 
[rpoB516 (20 pmol in 2 µL), rpoB526 (10 pmol in 1 µL), rpoB531 
(30 pmol in 3 µL), RIRm (reverse primer for rpoB531,516,526) 
(50 pmol in 5 µL), katG OF (10 pmol in 1 µL), katG5R (10 pmol 
in 1 µL), inhAP-15 (10 pmol in 1 µL), and inhAPF (10 pmol in 1 µL)], 
2 µL of genomic DNA (40ng) and 13 µL of AmpliTaq Gold master 
mix (ABI) (Table 2).18 The cycling parameters included an initial 
denaturation at 96°C for 3 min, 27 cycles of 95°C for 50 s, 64°C 
for 40 s, and 72°C for 1 min, and a final extension at 72°C for 
7 min. PCR products were analyzed by electrophoresis on 2.5% 
agarose gel and visualized with gel documentation.
Target  allele-specific   
primers     
Amplicon size (bp) 
katG 315 (5R)   5’-ATACGACCTCGATGCCGC         292
katG 315 (OF)   5’-GCAGATGGGGCTGATCTACG
rpoB 516 5’-CAGCTGAGCCAATTCATGGA    218
rpoB 531 5’-CACAAGCGCCGACTGTC           170
rpoB 526 5’-CTGTCGGGGTTGACCCA           185
RIRm 5’-TTGACCCGCGCGTACAC
inhA P15 5’-GCGCGGTCAGTTCCACA            270
inhA PF2 5’-CACCCCGACAACCTATCG
Table 2 - Primers used in MAS-PCR for detection of INH 
and RIF resistance mutations14 
Results 
Results of PCR analysis
In the PCR assay using IS6110 for confirmation of the 
isolates, all were positive and the results of amplification 
are presented in Fig. 1. Amplification of RRDR of rpoB gene 
yielded 270 bp products compared to DNA size marker in 
agarose gel electrophoresis (Fig. 2). inhA regulator sequence 
amplification of INH yielded 245 bp PCR products (Fig. 3), and 
katG codon 315 amplification of INH yielded 250 bp PCR 
products (Fig. 2).
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Results of DNA sequencing
The sequencing of the 250 bp region of katG codon 315 revealed 
point mutations at 5 different codons in 13.7% of the 80 MTB 
isolates. The sequencing of the 270 bp central region of the 
rpoB gene revealed point mutations at 7 different codons in 12 
(15%) of the 80 MTB isolates (Table 3). Among rpoB gene point 
mutations, in 2 isolates, mutation was observed in codon 531, 
causing TCG  to TTG substitution, in 7 isolates mutation was 
Fig. 3 - Results of MAS-PCR shown by 2.5 % agarose 
gel electrophoresis. The 292-bp band: the katG codon 
315-specific PCR product; the 218-bp band: rpoB codon 
516-specific PCR product; the 270-bp band: the  
15- promoter region of mabA-inhA–specific PCR product; 
the 185-bp band: rpoB codon 526-specific PCR product; the 
170-bp band: rpoB codon 531-specific PCR product.
                                 rpoB gene                                     rpoB gene
   AA (amino acid)           Nucleotide      AA (amino acid)           Nucleotide
Isolate   Codon    Change Change Isolate Codon    Change Change
54 512 Ser→Thr   AGC→ACC   4 315 Ser→Thr  AGC→ACC
39 527 Lys→Asn AAG→AAC   5 315 Ser→Thr  AGC→ACC
38 512 Ser→Thr   AGC→ACC   42 312 Ala→Glu  GCG→GAG
38 517 Gln→Lu   CAG→CCG   17 319 Ala→Val GCG→GTG
37 531 Ser→Lu    TCG→TTG    18 328 Trp→Val TGG→GTG
31 512 Ser→Thr   AGC→ACC   14 326 Thr→Pro  ACG→CCG
42 527 lys→Asn   AAG→AAC   13 12 Ala→Glu  GCG→GAG
13 527 lys→Asn   AAG→AAC   40 326 Thr→Gly  ACG→CCG
37 531 Ser→ Lue TCG→TTG    13 315 Ser→Thr  AGC→ACC
37 511 Lue→Met CTG→ATG   38 312 Ala→Glu  GCG→GAG
18 527 lys→Asn   AAG→AAC   59 319 Ala→Val GCG→GTG
50 527 lys→Asn   AAG→AAC
52 527 lys→Asn   AAG→AAC     
Table 3 - Distribution of mutations associated with RIF and INH resistance among MTB isolates
observed in codon 527, causing AAG to AAC and in 3 isolates 
mutation was observed in codon 512, causing AGC  to ACC 
substitution. One isolate had a mutation in codon 511 and one 
isolate had two mutations in codons 539 and 541 unexpectedly 
since these codons are out of the 81 bp region. No mutation 
was detected in the control RIF sensitive isolate (H37Rv). For 
INH, the most frequent mutation was observed in katG codons 
315 and 312, in which a change from AGC to ACC and GCG to 
GAG was observed, respectively. No mutation was observed 
in the inhA promotor region or in the INH sensitive control 
isolate (H37Rv).
Results of MAS-PCR
Out of 10 isolates that proved to have different mutations in 
katG gene, 3 isolates which showed mutation in codon 315 by 
sequencing, were detected by MAS-PCR method. These were 
accounted for 30% of total katG mutations. The results of 
PCR-nucleotide sequencing and MAS-PCR assay were identical 
for the inhA gene (Fig. 3).
Similarly, among 12 isolates that proved to have different 
mutations in rpoB gene, 2 isolates had a mutation in codon 531 
which were also detected by MAS-PCR.
Discussion
By using PCR and subsequent sequencing and MAS-PCR, we 
were able to detect the mutations related to drug resistance to 
RIF and INH. Based on the obtained results, we found out that 
MAS-PCR is a preferred method for detecting drug resistance 
in MTB in shorter time compared with PCR.
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In this study, based on PCR and sequencing, the most 
common mutations related to drug resistance were 
demonstrated as RIF (15%) and INH (13.7%). The results 
were not in accordance with a previous report from Ahvaz19 
in which the author observed that the most frequent 
mutations were substitutions in codons 516, 526 or 531 of the 
rpoB gene, which were found in 25 (83.3%) isolates. Mutations 
in codon 531 of the rpoB gene were detected in 16 (53.3%) of 
30 RIF resistant isolates.
A similar study from the middle-east reported INH 
resistance in their isolates with all mutations at codon 315 
of the katG gene. However, none of the reported mutations 
was AGC to ACC as found in our study.20
In the study of Yang et al.21 on the simultaneous 
detection of INH and RIF in 174 clinical isolates of MTB in 
Turkey, distinct PCR banding patterns were observed for 
different mutation profiles and the correlation between 
MAS-PCR results and DNA sequencing was 99.4%. Other 
studies used multiplex PCR to detect the mutations in 
rpoB and katG genes in 20 drug-resistant isolates of MTB 
from the Southeast of Mexico. Sequencing analysis showed 
93% mutations in the rpoB gene; of which 47% exhibited a 
mutation at 531 (S→L). Fifty-eight percent of their isolates 
showed mutations in katG; with 52% exhibiting a mutation 
at 315 (S→T).22 Also, the usefulness of MAS-PCR in detecting 
mutations was reported in a study by  Mokrousov et al.,23 in 
which they were able to detect rpoB mutations at the rate 
of 82.8%. The reported mutations were in the rpoB 531, 526 
and 516 codons. Similarly, in a study by  Rathore et al.,24 four 
mutations at rpoB codons 526, 531 and 12 were noticed in 16 
RIF resistant isolates and 7 mutations were identified in INH 
resistant isolates in the katG codon 315.
In a study on the detection of katG and inhA gene mutations 
in MTB by multiplex allele-specific PCR, of 31 INH-resistant 
isolates, mutations in the katG codon 315 were identified 
in 64.5% of the isolates by sequencing. From these, 19 were 
detected by MAS-PCR methods.25
Our findings showed that most of the resistance 
mutations to INH occurred in codon 315 and this was in 
agreement with other mentioned studies showing the major 
involvement of this codon in INH resistance all over the 
world. However, a variety of involved codons was reported 
for RIF resistance among MTB isolates in different studies. 
In our study, the main codon involved in RIF resistance was 
527, while similar studies reported several other codons for 
RIF resistance. 
In conclusion, although culture based phenotypic 
susceptibility test is the gold standard for detecting drug 
resistance in MTB and no molecular method can yet completely 
replace it, MAS-PCR provides a rapid screening tool for the 
majority of mutations occurring in genes related to INH and 
RIF antibiotics. However, the molecular assays only detected 
known mutations, which is the most important limitation in 
detection of drug resistance by such techniques. Based on 
the other studies, all mutations related to anti-TB drugs are 
not known yet. Since the prevalence of mutations may vary 
by geographic area, identification of a resistance-associated 
mutation can be instructive, but lack of a mutation in the target 
sequence must be interpreted with caution.
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